Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01778439 · ClinicalTrials.gov registry record · Phase 1
A Dose Escalation Study of OMP-52M51 in Subjects With Solid Tumors
A Phase 1 study, sponsored by OncoMed Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT01778439 is a Phase 1 study that has completed, run by OncoMed Pharmaceuticals. The registered enrollment target is 48 participants.
The verdict
NCT01778439, a Phase 1 study, has completed, sponsored by OncoMed Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
This is an open-label Phase 1a dose escalation study of single-agent OMP-52M51 in subjects with relapsed or refractory solid tumors. Study includes a dose escalation phase and expansion phase. Subjects will be assessed for safety, immunogenicity, pharmacokinetics, biomarkers, and efficacy.
Interventions
- DRUG OMP-52M51
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2013-02 |
| Est. Completion | 2016-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01778439
The ClinicalTrials.gov registry entry for NCT01778439 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is OncoMed Pharmaceuticals, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which OMP-52M51 is the first listed.
NCT01778439 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01778439 about?
NCT01778439 is a clinical study titled "A Dose Escalation Study of OMP-52M51 in Subjects With Solid Tumors". This is an open-label Phase 1a dose escalation study of single-agent OMP-52M51 in subjects with relapsed or refractory solid tumors. Study includes a dose escalation phase and expansion phase. Subjects will be assessed for safety, immunogenicity, pharmacokinetics, biomarkers, and efficacy.
What is the current status of trial NCT01778439?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2013-02. Estimated completion is 2016-07.
What interventions are being tested in trial NCT01778439?
The interventions under investigation include: OMP-52M51 (DRUG).
Who is sponsoring clinical trial NCT01778439?
This trial is sponsored by OncoMed Pharmaceuticals, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.